Treatment of Kearns‐Sayre syndrome with coenzyme Q 10
- 1 January 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 36 (1) , 45
- https://doi.org/10.1212/wnl.36.1.45
Abstract
We studied the metabolism of coenzyme Q10 (CoQ) and the effects of CoQ therapy in five patients with Kearns-Sayre syndrome (KSS). Although the mitochondrial fraction was increased in muscles from KSS patients, CoQ content was slightly low. CoQ synthesis was normal in fibroblasts from KSS patients. Administration of 120 to 150 mg/d of CoQ improved abnormal metabolism of pyruvate and NADH oxidation in skeletal muscle. CoQ therapy decreased CSF protein concentration and CSF lactate/pyruvate ratio. ECG abnormalities and neurologic symptoms also improved.This publication has 19 references indexed in Scilit:
- Lactate Homeostasis and Lactic AcidosisAnnals of Internal Medicine, 1980
- Synthesis of ubiquinone and cholesterol in human fibroblasts: Regulation of a branched pathwayArchives of Biochemistry and Biophysics, 1979
- Measurement of cytochromes in human skeletal muscle mitochondria, isolated from fresh and frozen stored muscle specimensBiochemical Medicine, 1978
- EFFECT OF VITAMIN-E-DEFICIENCY ON LEVEL OF SUPEROXIDE-DISMUTASE, GLUTATHIONE PEROXIDASE, CATALASE AND LIPID PEROXIDE IN RAT-LIVER1976
- Ophthalmoplegia PlusArchives of Neurology, 1968
- [39] Preparation and properties of succinic—cytochrome c reductase (complex II–III)Published by Elsevier ,1967
- The Inhibition of Mitochondrial Peroxidation by Ubiquinone and UbiquinolJournal of Biological Chemistry, 1966
- Spongiform encephalopathy with chronic progressive external ophthalmoplegiaNeurology, 1966
- Abnormal resting blood lactateThe American Journal of Medicine, 1961
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951